ArticleScience (New York, N.Y.)2015
Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.
Article in Science (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 87 citations in OpenAlex.
- Research hotspots and trend analyses of maximum biosafety level pathogens: A bibliometric study using China's 2023 catalogue of pathogens as an example.Biosafety and health · 2026Article
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
- Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review.PLoS neglected tropical diseases · 2026Article
- Comparison of the induction of neutralizing antibodies against Bas congo virus using several vaccine modalities.Scientific reports · 2025Article
- An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.Expert opinion on drug discovery · 2024Review
- Mapping of susceptibility loci for Ebola virus pathogenesis in mice.Cell reports · 2024Article
- RNA Editing as a General Trait of Ebolaviruses.The Journal of infectious diseases · 2023Article
- Review
- Ebola virus disrupts the inner blood-retinal barrier by induction of vascular endothelial growth factor in pericytes.PLoS pathogens · 2023Article
- Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects.Vaccines · 2022Review
- Development of a next-generation chikungunya virus vaccine based on the HydroVax platform.PLoS pathogens · 2022Article
- Cancer vaccines as promising immuno-therapeutics: platforms and current progress.Journal of hematology & oncology · 2022Review
- Ionizing Radiation Technologies for Vaccine Development - A Mini Review.Frontiers in immunology · 2022Review
- Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development.Open life sciences · 2021Review
- Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease.Pathogens (Basel, Switzerland) · 2020Review
- Article
- The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.Antiviral research · 2020Review
- Intradermal Immunization of EBOV VLPs in Guinea Pigs Induces Broader Antibody Responses Against GP Than Intramuscular Injection.Frontiers in microbiology · 2020Article
- Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.Nature medicine · 2019Article
- Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review.BMJ open · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Zaire ebolavirus is the causative agent of the current outbreak of hemorrhagic fever disease in West Africa. Previously, we showed that a whole Ebola virus (EBOV) vaccine based on a replication-defective EBOV (EBOVΔVP30) protects immunized mice and guinea pigs against lethal challenge with rodent-adapted EBOV. Here, we demonstrate that EBOVΔVP30 protects nonhuman primates against lethal infection with EBOV. Although EBOVΔVP30 is replication-incompetent, we additionally inactivated the vaccine with hydrogen peroxide; the chemically inactivated vaccine remained antigenic and protective in nonhuman primates. EBOVΔVP30 thus represents a safe, efficacious, whole-EBOV vaccine candidate that differs from other EBOV vaccine platforms in that it presents all viral proteins and the viral RNA to the host immune system, which might contribute to protective immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.